Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior

Gerbe, Anna; Alame, Mélissa; Dereure, O.; Gonzalez, S.; Durand, L; Tempier, Ariane; Oliveira, Laura de; Tourneret, Alicia; Costes-Martineau, Valérie; Cacheux, Valère; Szablewski, Vanessa

doi:10.1007/s00428-019-02570-4

Cited by 20 publications

(17 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the cell morphology (dyscohesive large pleomorphic cells), intralymphatic and extravascular components, as well as careful clinical correlation, especially follow‐up of the patient, can help to establish the correct diagnosis. Moreover, a Treg phenotype and negativity for cytotoxic granules, such as shown in the current case, can be valuable supplementary aid . On the other hand, differently from the current case, systemic ALCL is an aggressive disease with poor outcome, with frequent expression of cytotoxic granules and negativity for FOXP3 .…”

mentioning

confidence: 52%

“…Moreover, a Treg phenotype and negativity for cytotoxic granules, such as shown in the current case, can be valuable supplementary aid . On the other hand, differently from the current case, systemic ALCL is an aggressive disease with poor outcome, with frequent expression of cytotoxic granules and negativity for FOXP3 . Also, large necrotic eschar‐like lesions (measuring between 1 and 4 cm), exhibiting common recurrences, and showing by microscopy angiocentric and angiodestructive infiltrates of CD30+/CD8+ atypical lymphocytes, characterizing lymphomatoid papulosis (LyP) type E, were not observed in the current case.…”

mentioning

confidence: 54%

See 1 more Smart Citation

Benign atypical intralymphatic CD30+ lymphoid proliferation with activated regulatory T‐cell phenotype in the oral cavity

et al. 2019

View full text Add to dashboard Cite

mentioning

confidence: 52%

mentioning

confidence: 54%

Benign atypical intralymphatic CD30+ lymphoid proliferation with activated regulatory T‐cell phenotype in the oral cavity

et al. 2019

View full text Add to dashboard Cite

“…Kantekure et al 11 reported that all stages of CTCL cases showed immunostaining for PD-L1 (rabbit PD-L1 antibody, Lifespan Biosciences, Seattle, WA, USA) on most of the atypical lymphocytes, and that nPD-L1 expression in cases with CTCL/MF increases with disease progression and large-cell transformation. Gerbe et al 12 using immunostaining with anti-PD-L1 clone E1L3M, reported nPD-L1 expression (6/13 cases, 46.2%) and microenvironment PD-L1 expression (7/13 cases, 53.8%) in primary cutaneous ALCL.…”

Section: Npd-l1 In In Ln Lesion Of Cd30+ Pcltcl 809mentioning

confidence: 99%

“…9,10 However, PD-L1 expression remains unclarified in CTCL/LPDs, although a few reports have documented neoplastic PD-L1 (nPD-L1) expression in MF, that increased with histological progression, and nPD-L1 expression in PC-ALCL. 11,12 Here, we report two cases with primary cutaneous large T-cell lymphoma (PCLTCL) with CD30 expression that developed secondary nodal lesions mimicking CHL. We emphasize the PD-L1 expression on the tumor cells in nodal lesions as contrasted with its scarcity on those of their primary cutaneous lesions.…”

Section: Introductionmentioning

confidence: 99%

“…PD‐L1 expression is well studied in CHL and this research recently led to the assertion that PD‐L1/PD‐L2 genetic alterations define CHL, with an universal expression of PD‐L1 on Hodgkin and Reed‐Sternberg cells (HRS) 9,10 . However, PD‐L1 expression remains unclarified in CTCL/LPDs, although a few reports have documented neoplastic PD‐L1 (nPD‐L1) expression in MF, that increased with histological progression, and nPD‐L1 expression in PC‐ALCL 11,12 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced PD‐L1 expression on tumor cells in primary cutaneous large T‐cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases

Takahashi

Tsuchida

Baba

et al. 2020

Pathology International

View full text Add to dashboard Cite

Neoplastic PD-L1 (nPD-L1, clone SP142) expression remains unclear in cutaneous T-cell lymphoma (CTCL), although it is well-documented in classic Hodgkin lymphoma (CHL). Here, we report two cases of primary cutaneous large T-cell lymphoma (PCLTCL) with CD30 expression that developed secondary nodal lesions morphologically mimicking CHL, and describe their PD-L1 expression. Our two cases (52-and 60-year-old males) had long-standing clinical courses of CTCL. Their PCLTCL with CD30 expression developed nodal lesions, having a nodular growth pattern containing scattered CD30+ Hodgkin and Reed-Sternberg-like and/or lacunar cells that expressed CD15 but did not harbor Epstein-Barr virus. Their differential diagnosis from CHL was challenging. A diagnosis of PCLTCL with secondary nodal involvement featuring CHL mimicry was based on comparison of the primary and secondary lesions. In one case, shared expression of the same T-cell antigen was revealed by immunohistochemistry, and in the other, identical clonal TCR rearrangement was demonstrated by polymerase chain reaction (PCR). Interestingly, nPD-L1 was expressed on more than 50% of the tumor cells in the secondary nodal lesions, but on very few in the primary cutaneous lesions, in both cases. This is the first report of nPD-L1 expression greatly increasing with PCLTCL tumor progression to nodal involvement.

show abstract

A genetic profiling guideline to support diagnosis and clinical management of lymphomas

Sánchez-Beato,

Méndez,

Guirado

et al. 2023

Clin Transl Oncol

View full text Add to dashboard Cite

The new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization Classification of Lymphoid Neoplasms) include genetics as an integral part of lymphoma diagnosis, allowing better lymphoma subclassification, patient risk stratification, and prediction of treatment response. Lymphomas are characterized by very few recurrent and disease-specific mutations, and most entities have a heterogenous genetic landscape with a long tail of recurrently mutated genes. Most of these occur at low frequencies, reflecting the clinical heterogeneity of lymphomas. Multiple studies have identified genetic markers that improve diagnostics and prognostication, and next-generation sequencing is becoming an essential tool in the clinical laboratory. This review provides a “next-generation sequencing” guide for lymphomas. It discusses the genetic alterations of the most frequent mature lymphoma entities with diagnostic, prognostic, and predictive potential and proposes targeted sequencing panels to detect mutations and copy-number alterations for B- and NK/T-cell lymphomas.

show abstract

Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior

Cited by 20 publications

References 50 publications

Benign atypical intralymphatic CD30+ lymphoid proliferation with activated regulatory T‐cell phenotype in the oral cavity

Benign atypical intralymphatic CD30+ lymphoid proliferation with activated regulatory T‐cell phenotype in the oral cavity

Enhanced PD‐L1 expression on tumor cells in primary cutaneous large T‐cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases

A genetic profiling guideline to support diagnosis and clinical management of lymphomas

Contact Info

Product

Resources

About